Literature DB >> 8311080

Pathogenesis of secondary hyperparathyroidism.

E Slatopolsky1, J A Delmez.   

Abstract

The past 20 years has witnessed a dramatic improvement in our understanding of the factors involved in the pathogenesis of secondary hyperparathyroidism in chronic renal insufficiency. The major causes are retention of phosphorus, relatively low levels of serum calcium, and decreased 1,25-(OH)2D3 (calcitriol) levels. Abnormalities in vitamin D metabolism are responsible for a series of events that result in a state of abnormal calcium-regulated parathyroid hormone (PTH) secretion. In patients with a moderate degree of renal insufficiency, phosphate restriction suppresses PTH secretion by increasing serum calcitriol. However, studies in patients and dogs with advanced renal insufficiency have clearly demonstrated that phosphate per se, independent of the levels of calcitriol or ionized calcium, has an important effect on the secretion of PTH. In addition, low levels of calcitriol, characteristically seen in patients with advanced renal insufficiency, may affect the response of the parathyroid glands to serum ionized calcium. A shift in the set-point for calcium-regulated PTH secretion requires a much higher concentration of serum calcium to suppress the release of PTH. Studies evaluating the administration of intravenous calcitriol have clearly demonstrated that the parathyroid glands become more sensitive to calcium and the suppression of PTH secretion can be achieved with physiologic levels of ionized calcium. In addition, the number of calcitriol receptors in the parathyroid glands of patients and experimental animals with advanced renal failure is low. Investigators have shown that the administration of calcitriol to normal rats increases the mRNA of the vitamin D receptor. Thus, calcitriol upregulates the number of its own receptor.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8311080     DOI: 10.1016/s0272-6386(12)80977-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  15 in total

Review 1.  Renal osteodystrophy.

Authors:  E A González; K J Martin
Journal:  Rev Endocr Metab Disord       Date:  2001-04       Impact factor: 6.514

2.  Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.

Authors:  Larry A Greenbaum; Ryszard Grenda; Ping Qiu; Irene Restaino; Amy Wojtak; Ana Paredes; Nadine Benador; Joel Z Melnick; Laura A Williams; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

3.  Mono- and polyphosphates have similar effects on calcium and phosphorus metabolism in healthy young women.

Authors:  Heini J Karp; Virpi E Kemi; Christel J E Lamberg-Allardt; Merja U M Kärkkäinen
Journal:  Eur J Nutr       Date:  2012-07-05       Impact factor: 5.614

4.  Phosphate administration increases both size and number of parathyroid cells in adult rats.

Authors:  Q Wang; E Paloyan; A M Parfitt
Journal:  Calcif Tissue Int       Date:  1996-01       Impact factor: 4.333

5.  Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease.

Authors:  Jutta Muscheites; Marianne Wigger; Erdmute Drueckler; Dagmar-Christiane Fischer; Guenther Kundt; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2008-05-27       Impact factor: 3.714

Review 6.  The parathyroid calcium receptor: a novel therapeutic target for treating hyperparathyroidism.

Authors:  E F Nemeth; M E Steffey; J Fox
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

Review 7.  Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.

Authors:  Cheryl P Sanchez
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 8.  Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.

Authors:  William G Goodman
Journal:  Pediatr Nephrol       Date:  2003-10-28       Impact factor: 3.714

Review 9.  Safety of new phosphate binders for chronic renal failure.

Authors:  Mahmoud Loghman-Adham
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.

Authors:  Alastair J Hutchison; Maurice Laville
Journal:  Nephrol Dial Transplant       Date:  2008-06-24       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.